News Search Results
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla® EU SmPC.
More news about: UCB
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1) designed to inhibit the spread of SOD1 pathology in the CNS of ALS patients. AP-101 received orphan drug designations from FDA, EMA and Swissmedic. The Phase 2 study evaluated safety, tolerability, pharmacodynamic
More news about: AL-S Pharma AG
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
Use of Emapalumab is associated with rapid and sustained benefits in pHLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109.
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Hypersensitivity to diazepamAcute narrow-angle glaucomaCentral Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Dec 05, 2025, 09:00 ET Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.Suicidal Behavior and Ideation:Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts
More news about: Jazz Pharmaceuticals plc
Dec 04, 2025, 09:00 ET Cumulus Neuroscience Presents Data at CTAD 2025 Annual Meeting
digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today presented new analysis from its CNS-101 study at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego, California.
More news about: Cumulus Neuroscience
Dec 04, 2025, 08:12 ET UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
reduction of NAYZILAM may precipitate acute withdrawal reactions, which can be life-threatening. NAYZILAM may cause an increased CNS-depressant effect when used with alcohol or other CNS depressants. Concomitant use with moderate or strong CYP3A4 inhibitors may result in prolonged sedation due to a decrease
More news about: UCB
Dec 04, 2025, 07:00 ET SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer
of disease pathways including Lp-PLA21, beta amyloid and LRRK22 as well as the ongoing discovery of novel treatments for other CNS disorders.
More news about: SciNeuro Pharmaceuticals
Dec 04, 2025, 07:00 ET Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis
biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered
More news about: Neurimmune
Dec 04, 2025, 04:42 ET Generic Injectables Market Dominated by Hospital Pharmacies with 61.23% Share as Online Pharmacies Surge at 18.06% CAGR Through 2030, Reports Mordor Intelligence
Generics By Therapeutic Area Oncology Anti-infectives Cardiovascular Diabetes & Metabolic CNS Disorders Others By Route of Administration Intravenous Intramuscular Sub-cutaneous Others By
More news about: Mordor Intelligence Private Limited
Dec 03, 2025, 14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
distribution, and neuroinflammatory pathways.Recent highlights:GLP studies underway with positive PK, biodistribution, and CNS-penetration modelingRegulatory-facing package expected to mature in 2026.GDNF-Based Weight-Loss & Metabolic Program (VA
More news about: Hoth Therapeutics, Inc.
Dec 03, 2025, 09:00 ET Benuvia Operations Announces Strategic Partnership with Cannovation Clinical Research Partners to Deliver Fully Integrated Solutions for Controlled-Substance Therapeutics
emerging CNS therapeuticsComprehensive commercialization support to accelerate the safe, compliant delivery of new medicines to patientsAccelerating Innovation in Psychedelics, Cannabinoids, and Novel TherapeuticsAs research into psychedelic and cannabinoid-based CNS treatments
More news about: Benuvia Operations, LLC
Dec 02, 2025, 09:00 ET Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
business development, commercial strategy, and R&D leadership in advancing first- or best-in-class therapies for cardiometabolic, rare/genetic, and CNS diseases. He founded the precision cardiology therapeutic area at BioMarin, serving as Head of Cardiovascular R&D, where he built an extensive portfolio
More news about: Thryv Therapeutics Inc.
Dec 02, 2025, 07:00 ET Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
differentiation. Th1/Th17 cells play a central role in central nervous system (CNS) inflammatory diseases such as multiple sclerosis (MS). Inhibiting TYK2 reduces the activation of pro-inflammatory T cells, thus lowering CNS inflammation. LNK01006 demonstrated high brain penetration in preclinical species
More news about: Lynk Pharmaceuticals Co., Ltd.
Dec 02, 2025, 06:59 ET Garmin G5000H selected for Brazilian Air Force UH-60 Black Hawk helicopters
Marketing, Programs & SupportThe G5000H provides operators with the latest communication, navigation, surveillance air traffic management (CNS/ATM) capabilities with COTS solutions based on Garmin's modern open system architecture design. Mission management systems can be integrated along with
More news about: Garmin International, Inc.
Dec 01, 2025, 09:00 ET Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting
PRECAUTIONSSomnolenceDIACOMIT can cause somnolence. Monitor patients for somnolence, particularly when DIACOMIT is used concomitantly with other CNS depressants or clobazam, which is also known to cause somnolence.Decreased Appetite and Decreased WeightDIACOMIT can cause decreases
More news about: Biocodex, Inc.
Nov 28, 2025, 05:46 ET CRO Industry to Hit USD 127.77 Billion by 2030 Driven by Advanced Clinical Trial Models and Led by North America, Says Mordor Intelligence
ServicesConsulting ServicesBy Therapeutic Area OncologyInfectious DiseasesCentral Nervous System (CNS) DisordersImmunological DisordersCardiovascular DiseasesRespiratory DisordersDiabetesOther Therapeutic AreasBy
More news about: Mordor Intelligence Private Limited
Nov 27, 2025, 10:01 ET Orphan Drugs Market to Surge to USD 486.51 Billion by 2032 as Rare Disease Innovation, Gene Therapies & Precision Medicine Reshape Global Healthcare
beta-thalassemia, and bone marrow failure syndromes are seeing breakthrough approvals in gene therapy and biologics.Central Nervous System (CNS)CNS held 12% (USD 26.8 billion). Rare neuromuscular disorders, inherited neurological conditions, mitochondrial diseases, and epilepsy subtypes
More news about: DataM Intelligence 4 Market Research LLP
Nov 27, 2025, 04:04 ET Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
lives of people with CNS disorders through continuous innovation and strong partnerships. With this launch, we are taking another important step in our journey to improve the daily lives of people with epilepsy. This breakthrough embodies our commitment to digital personalised CNS care, helping patients
More news about: Neuraxpharm
Nov 26, 2025, 21:39 ET SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights
More news about: SK Biopharmaceuticals. Co., Ltd.
Nov 26, 2025, 17:26 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:25 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:23 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 17:15 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.